Navigation Links
Bioniche Presents E. coli O157:H7 Vaccine Data to World Buiatrics Congress in Budapest, Hungary
Date:7/10/2008

BELLEVILLE, ON, July 10 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, presented data regarding its E. coli O157:H7 cattle vaccine at the XXV World Buiatrics Congress in Budapest, Hungary today. The presentation was made by Dr. Dragan Rogan, Vice-President, Bioniche Animal Health Research & Development. It was entitled, "Vaccination of Cattle with E. coli O157:H7 Type III Secretion Proteins as a Pre-Slaughter Intervention Method to Reduce E. coli O157:H7 Prevalence", and was co-authored by Dr. David Smith, Dr. Rod Moxley, Dr. Andy Potter and Julie Yome.

The World Buiatrics Congress is the largest event of its kind in the cattle industry, and is attended by scientists from universities and research institutes, practitioners working with dairy and beef cattle and other ruminants, consultants, post-docs, PhDs and graduate students of veterinary medicine and animal science from around the world.

The Bioniche vaccine is the world's first vaccine that may be used as an on-farm intervention to reduce the amount of E. coli O157:H7 shed by cattle. Bioniche and its collaborators have been moving the vaccine towards commercial availability for eight years and it has been extensively tested at the University Nebraska-Lincoln, with efficacy results now being published in peer-reviewed scientific journals, most recently, the Journal of Food Protection, in November, 2007.

In his presentation in Budapest, Dr. Rogan summarized numerous studies that have been completed with the Bioniche vaccine over the last five years involving more than 30,000 cattle. In one study, calves were vaccinated with three doses and challenged with E. coli O157:H7 14 days later. There was a 2.28 log10 reduction in the magnitude of shedding in vaccinated animals compared to controls. In another study, with a three-dose vaccination and natural exposure to E. coli O157:H7, vaccinated animals w
'/>"/>

SOURCE Bioniche Life Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Bioniche Hosts Veterinarians and Food Industry Reps at Two-Day E. coli O157:H7 Vaccine Conference
2. Bioniche Secures Final Financing to Scale-up E. coli O157:H7 Vaccine Production
3. Bioniche Presents E. coli O157:H7 Vaccine Data to International Congress of Medical Microbiology in Serbia
4. Bioniche Presents Pre-Clinical Research at Two International Conferences
5. Bioniche Updates re: Mycobacterial Cell Wall Technology Platform
6. Bioniche Reports Fiscal 2008 Third Quarter
7. Bioniche Appoints U.S. President of Food Safety
8. Bioniche Reports the Passing of its Board Chair
9. Bioniche Converts a Portion of its Debt to Equity
10. Bioniche Receives Fast Track Designation For First-Line Bladder Cancer Therapy
11. Bioniche Pharma Chooses TrackWise for its Deviation Control Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2014)... and industry leaders visited the New Jersey Institute ... Joel S. Bloom for the launch of the ... that provides a new model for business innovation ... education assets and investment. U.S. Senator Cory Booker, ... Joe Taylor, New Jersey Lieutenant Governor Kim Guadagno, ...
(Date:4/22/2014)... have characterized a set of clock genes that drive ... of species, from flies to humans. Over 15 mammalian ... are more. A team from the Perelman School of ... approaches could find them. , To accelerate clock-gene ... of Pharmacology and first author Ron Anafi, MD, PhD, ...
(Date:4/22/2014)... April 22, 2014 Researchers at UT Southwestern Medical ... from depression . , A team of ... by which ghrelin (a hormone with natural anti-depressant properties) ... potentially powerful new treatment for depression in the form ... The study, published online in April,s issue of ...
(Date:4/22/2014)... pregnancy among women using a newer method of planned ... greater over a 10-year period than using the more ... Yale University and UC Davis has found. , ... , the study found the higher risk of pregnancy ... name Essure. , "This study provides essential information ...
(Date:4/22/2014)... International Communication Association will hold its 64th annual ... of the 2014 conference will explore what the ... society. , Featuring over 2,300 academic papers on ... representing over 40 countries, the ICA conference is ... world. This year,s conference features sessions that focus ...
Breaking Medicine News(10 mins):Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Bioinformatics profiling identifies a new mammalian clock gene 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2
... three of the 12 newly awarded grants from the ... prevention and treatment of prison and jail inmates. The ... are part of Seek, Test, and Treat: Addressing HIV ... initiative to date to aggressively identify and treat HIV-positive ...
... have hypertension are much more likely to have learning ... a new University of Rochester Medical Center (URMC) study ... In fact, when variables such as socio-economic levels are ... likely to have cognitive problems. "This ...
... Jenifer Goodwin HealthDay Reporter , MONDAY, Nov. 8 ... people who have never smoked may be a different disease ... genetic characteristics of lung cancer tumors in 30 people who ... The tumors of people who had never smoked had ...
... UC Davis researchers have found a new pathway for repairing ... week in the journal Proceedings of the National Academy ... greater capacity to repair oxidative damage," said Peter Beal, professor ... paper. As part of its inflammatory response, the body,s ...
... 2010) Results from a European Observational Study, ... at the Tenth International Congress on Drug Therapy ... of discontinuation and sustained virologic suppression with REYATAZ ... to five years. 1 The aim ...
... Multidetector computed tomography (CT) helps pinpoint the causes ... potentially speeding the delivery of life-saving treatments, according to ... of Radiology . "Our results suggest ... for identifying the cause of acute ischemic stroke," said ...
Cached Medicine News:Health News:Miriam receives $1.5 million from NIH to 'seek, test and treat' inmates with HIV 2Health News:Miriam receives $1.5 million from NIH to 'seek, test and treat' inmates with HIV 3Health News:Children with high blood pressure more likely to have learning disabilities 2Health News:Lung Cancer in Smokers, Nonsmokers May Be a Different Disease 2Health News:Lung Cancer in Smokers, Nonsmokers May Be a Different Disease 3Health News:New DNA repair pathway 2Health News:Study shows durable viral suppression of boosted REYATAZ in treatment-experienced HIV patients 2Health News:Using CT, radiologists can pinpoint cause of some strokes 2
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: ... the Office of Fair Trading (OFT) approval condition to the announced ... (NASDAQ: VPHM).   As a result of the waiver, ... expects to complete the tender offer on January 24, 2014 following ...
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... Inc. (NASDAQ: VVUS ) today announced ... medical claims data on oral clefts (OC) associated ... study, known as FORTRESS for Fetal Outcome Retrospective ... to topiramate either alone (monotherapy) or in combination ...
... Dec. 21, 2011 Isentress (raltegravir) was approved today by ... antiretroviral drugs for the treatment of HIV-1 infection for children ... ) The drug is part of a ... works by slowing the spread of HIV in the body. ...
Cached Medicine Technology:VIVUS Reports Topline Findings From FORTRESS 2VIVUS Reports Topline Findings From FORTRESS 3VIVUS Reports Topline Findings From FORTRESS 4VIVUS Reports Topline Findings From FORTRESS 5VIVUS Reports Topline Findings From FORTRESS 6FDA Expands Use of HIV Drug Isentress to Children and Adolescents 2FDA Expands Use of HIV Drug Isentress to Children and Adolescents 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: